The third issue of Legalease's zappy little bimonthly Life Sciences, Law & Business has now been published. It contains, among other things, the following features:
* "IP Valuation -- Evaluation in Phamaceutical Projects" by PricewaterhouseCoopers' Lucinda Spicer and Jo Pisani (or should that be LucindaspicerandJopisani?);
* "Multi-party Actions -- Who Pays the Costs?" by Anna McKay (Roiter Zucker);
* "Global Healthcare -- TRIPs and Access to Medicines" by veteran patent expert Philip Grubb (Novartis International).
The IPKat says "enjoy".
Do you want to reuse the IPKat content? Please refer to our
Policies section.
If you have any queries or requests for permission, please get in touch with the IPKat team.
Comments
Post a Comment
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html